Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status Prescription
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 60505-3250; 53873-075; 53873-073; 55773-0589; 49702-204; 49702-203; 50742-623; 65015-701; 68180-603; 50742-624; 65862-259; 53873-074; 54838-566; 31722-752; 64380-711; 49702-205; 31722-001; 70159-001; 52482-003; 64380-710; 31722-753; 68554-0043; 65862-026; 33342-001; 69097-167; 70518-3267; 57237-274; 65015-756; 70518-2067; 70518-2070; 67835-0017; 0173-0662; 53104-7538; 60687-362; 0173-0663; 60505-3252; 53104-7677; 65862-025; 68180-602; 65862-055; 68554-0016; 66993-478; 31722-754; 65862-577; 69097-166; 42385-714; 33342-002; 60505-3251; 60429-354; 60429-353; 0904-6583
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Convulsion neonatal17.12.03.017; 18.04.04.0030.009276%Not Available
Cough22.02.03.001--
Cryptorchism21.15.01.001; 05.05.02.002; 03.03.01.0010.020870%Not Available
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Death neonatal18.04.01.002; 08.04.01.0020.004235%
Dehydration14.05.05.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.013914%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug interaction08.06.03.001--Not Available
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dysphonia19.19.03.002; 17.02.08.004; 22.02.05.0050.004638%
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.0030.009276%Not Available
Dysuria20.02.02.002--
Ear malformation03.13.02.001; 04.06.02.0010.004638%Not Available
Electrolyte imbalance14.05.01.002--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 13 Pages